Sensus Healthcare (SRTS): Customer Relationships, Revenue Concentration, and Strategic Implications

Sensus Healthcare manufactures and markets superficial radiation therapy (SRT) devices and related services to dermatology and oncology providers, monetizing through equipment sales, service contracts, and, since mid‑2024, multi‑year equipment leases under its subsidiary Sensus Healthcare Services, LLC. The business is highly U.S.‑centric and dependent on a narrow set of commercial relationships, while the company has actively reshaped its product portfolio via asset sales. For a focused view of counterparties and contract levers, see Null Exposure’s platform for investor‑grade relationship intelligence: https://nullexposure.com/.

Quick read for investors: what matters now

Revenue model: device sales + services + newly scaled 60‑month leases that auto‑renew annually.
Concentration risk: one U.S. customer accounted for 73% of revenues in FY2024.
Geography: ~96% of sales in the U.S. for FY2024.
Product focus: the SRT‑100 line is the core revenue engine through Dec 31, 2024.
Recent portfolio action: Sensus divested Sculptura ART/brachytherapy assets to Empyrean for $15 million.

If you evaluate customer relationships for investment or operations, the clearest read is that Sensus offers meaningful revenue visibility from leases but remains exposed to single‑customer concentration and U.S. market cyclicality. For deeper counterparty mappings and primary source links, visit Null Exposure: https://nullexposure.com/.

The customer relationships on record

Empyrean Medical Systems — Sensus sold its Sculptura targeted directional anisotropic radiation therapy (ART) and brachytherapy assets to Empyrean Medical Systems for $15 million, a transaction tied to prior fiscal activity and reported publicly in March 2026. This sale reduces Sensus’s exposure to the Sculptura line and concentrates attention back on the SRT product family. (MPO Magazine, March 10, 2026: https://www.mpo-mag.com/breaking-news/sensus-healthcare-sells-sculptura-to-empyrean-medical-for-15m/)

Company‑level constraints that drive customer economics

The following constraints are drawn from Sensus’s own disclosures and are best read as company‑level signals that shape how customers contract, the criticality of those relationships, and revenue durability.

Contracting posture — long‑term leases: Beginning in the quarter ended June 30, 2024, Sensus expanded leasing via subsidiary Sensus Healthcare Services, LLC; leases typically have an initial 60‑month term and automatic one‑year renewals. This alters the revenue mix toward recurring, term‑based streams and creates a multi‑year service and maintenance relationship profile (company filing, quarter ended June 30, 2024).
Geographic concentration — highly U.S. centric: 96% of sales were to U.S. customers in FY2024, up from 91% in FY2023, which concentrates macro and reimbursement risk in one market (company filings for years ended Dec 31, 2024 and 2023).
Revenue concentration — a single large customer: One U.S. customer accounted for 73% of revenues in FY2024 (61% in FY2023), making Sensus unusually exposed to counterparty performance or contract renewal with that buyer (company filings for year ended Dec 31, 2024).
Relationship stage — active leasing program: The lease initiative is live and generating ongoing contractual relationships with dermatology clinics starting in mid‑2024; this is an active, company‑led shift in commercial approach (company filing, quarter ended June 30, 2024).
Segment focus — core SRT product dominance: From inception through Dec 31, 2024, the SRT‑100 product line and related services were the primary revenue source, indicating product concentration and limited diversification by end of 2024 (company disclosures).

These constraints collectively mean Sensus has greater revenue visibility from lease cashflows than a pure capital‑sale model, but material counterparty and geographic concentration elevate downside risk if the principal customer or U.S. reimbursement dynamics change.

What the numbers tell investors

Sensus reported TTM revenue of approximately $27.5 million with gross profit of about $11.9 million, and it currently carries a market capitalization near $65 million. The balance between negative net income metrics (Diluted EPS TTM −$0.47) and a strategy to convert device sales into multi‑year lease contracts positions valuation sensitivity around lease renewal rates, service margins, and retention of the large contributing customer. Because the SRT product line has driven revenue since inception through 2024, product reliability, support, and clinical adoption are the operational levers that determine whether leases convert to long‑run annuity revenue.

For a deeper counterparty map and to monitor changes in concentration over time, explore Null Exposure’s tools for investor due diligence: https://nullexposure.com/.

Risks and upside — how to think about tradeoffs

Concentration risk (primary downside): With one customer supplying 73% of revenue in FY2024, contract non‑renewal or payment disruption would be material. This single‑counterparty exposure dominates credit and revenue scenarios.
Leasing program (structural upside and operational challenge): Leases create predictable cashflows and higher lifetime revenue per device if retention and service upsell remain strong, but they introduce capital intensity and residual equipment risk if technology cycles accelerate. The 60‑month initial term with automatic renewals supports revenue visibility.
U.S. dependence (market exposure): ~96% U.S. sales focus upside on domestic policy and payer dynamics while limiting international diversification benefits.
Product portfolio streamlining: The sale of Sculptura assets to Empyrean for $15 million reduces product line breadth and may concentrate go‑to‑market efforts on the SRT line, simplifying operations but increasing single‑product sensitivity (MPO Magazine, March 2026).

Bottom line and recommended next steps

Sensus operates at the intersection of medical device sales and service‑oriented leasing, with meaningful revenue visibility from multi‑year leases but acute concentration risk that dominates valuation sensitivity. Investors and operators should prioritize monitoring the major customer’s contract status, lease renewal rates, and service margin trajectory.

Actions:

For active monitoring of Sensus customer relationships and concentration dynamics, review Null Exposure’s relationship intelligence: https://nullexposure.com/.
If performing fundamental due diligence, obtain the counterparty contract schedules and retention metrics for leases initiated post‑June 2024 to quantify annuity conversion and residual risk.
Track clinical adoption and service economics of the SRT‑100 family versus divested assets (Sculptura sale) to evaluate product concentration impacts.

Sensus’s case is a classic tradeoff: recurring revenue and clearer servicing economics versus existential risk if the dominant customer alters buying behavior. For a continual feed of customer‑level changes and hard source links, visit Null Exposure: https://nullexposure.com/.

SRTS customer relationships